IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
Seeking Alpha8/18/2026Neutral
IDXX
IDEXX Laboratories IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$43.02B
P/E Ratio
38.76
EPS
$14.09
Beta
1.54
52W High
$769.98
52W Low
$518.55
50-Day MA
$561.19
200-Day MA
$617.50
Dividend Yield
—
Profit Margin
25.00%
Forward P/E
37.31
PEG Ratio
3.37
About IDEXX Laboratories Inc
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Fundamentals
| Revenue (TTM) | $4.55B |
| Gross Profit (TTM) | $2.84B |
| EBITDA | $1.62B |
| Operating Margin | 35.00% |
| Return on Equity | 74.20% |
| Return on Assets | 27.10% |
| Revenue/Share (TTM) | $57.17 |
| Book Value | $20.45 |
| Price-to-Book | 26.92 |
| Price-to-Sales (TTM) | 9.45 |
| EV/Revenue | 9.73 |
| EV/EBITDA | 27.41 |
| Quarterly Earnings Growth (YoY) | 17.60% |
| Quarterly Revenue Growth (YoY) | 9.70% |
| Shares Outstanding | $78.78M |
| Float | $78.50M |
| % Insiders | 0.22% |
| % Institutions | 96.78% |
Historical Volatility
HV 10-Day
30.85%
HV 20-Day
28.07%
HV 30-Day
30.80%
HV 60-Day
31.87%
HV Rank
49.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($698.92 target)
4
Strong Buy5
Buy5
Hold1
Strong SellLatest News
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices.
MarketBeat8/14/2026Positive
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research8/12/2026Positive
Here is Why Growth Investors Should Buy Idexx (IDXX) Now
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research8/6/2026Positive
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
Zacks Investment Research8/4/2026Positive
IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript
IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript
Seeking Alpha8/4/2026Neutral
IDEXX Laboratories Q2 Earnings Call Highlights
IDEXX Laboratories NASDAQ: IDXX reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing strong recurring diagnostics revenue, product-cost benefits and continued momentum from new product introductions.
MarketBeat8/4/2026Positive
Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research8/4/2026Positive
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $4.27 per share, beating the Zacks Consensus Estimate of $3.95 per share. This compares to earnings of $3.63 per share a year ago.
Zacks Investment Research8/4/2026Positive
IDEXX Laboratories Announces Second Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company reports revenues of $1,217 million for the second quarter of 2026, an increase of 10% as reported and 9% organic, driven by Companion Animal Group ("CAG") growth of 9% as reported and organic, Water revenue growth of 15% as reported and 13% organic, and LPD revenue growth of 11% as reported and 9% org.
Business Wire8/4/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IDXX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026